Kalaris to present TH103 Phase 1a data at retina specialists meeting

June 23, 2026 8:00 AM

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) announced it will present Phase 1a clinical data for its investigational drug TH103 at the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found